Stock listing

Hamburg:J7Z Jazz Pharmaceuticals plc Aktie

German listing (Hamburg) of Jazz Pharmaceuticals plc · home listing NASDAQ:JAZZ

Follow Jazz Pharmaceuticals plc into a list and get an email when it puts out news.

Home listing price · NASDAQ:JAZZ

$230.26 USD -17.51 (-7.1%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:JAZZ

Past year +31.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$227.95 – $238.59 USDNov 20, 2026
Volume
984,644 sharesNov 20, 2026
Market cap
$14.95B USDAt the close on Nov 20, 2026 · price × 64.91M shares outstanding
52-week range
$156.95 – $266.38 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$207.2M USDMedian day 740,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Jazz Pharmaceuticals plc logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:JAZZ · Home$230.26 USD-17.51 (-7.1%)984,644$236.00$238.59$227.95$247.77Close on Nov 20, 2026
Frankfurt:J7Z€209.20 EUR-5.50 (-2.6%)—€209.70€213.70€209.20€214.70Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:JAZZ · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$230.26-17.51-7.1%$236.00$238.59$227.95984,644
$247.77+7.06+2.9%$240.34$248.17$240.10721,463
$240.71+0.94+0.4%$239.63$242.38$237.85499,452
$239.77-1.78-0.7%$243.30$244.61$238.94490,227
$241.55+1.18+0.5%$241.77$243.25$235.89496,700
$240.37-7.87-3.2%$248.80$249.97$239.67584,272
$248.24+2.81+1.1%$245.77$248.97$243.76592,829
$245.43+1.885+0.8%$243.55$246.47$240.77576,699
$243.55+8.785+3.7%$236.00$244.37$235.14885,894
$234.76+7.44+3.3%$226.66$237.76$226.12886,982
$227.32-7.34-3.1%$233.20$233.80$227.05670,555
$234.66+4.92+2.1%$233.23$234.67$228.45899,031
$229.74+15.30+7.1%$225.37$234.78$218.531,680,855
$214.44-1.54-0.7%$215.84$218.36$213.811,037,126
$215.98+8.15+3.9%$209.63$216.38$209.361,212,681
$207.83+2.77+1.4%$207.00$211.32$205.73773,557
$205.06-1.72-0.8%$204.38$206.77$202.30816,104
$206.78+1.08+0.5%$206.31$207.67$204.04605,810
$205.70-8.30-3.9%$215.29$216.43$205.11969,992
$214.00-0.65-0.3%$213.09$215.35$211.49560,601
$214.65+2.68+1.3%$211.38$215.24$210.26783,806
$211.97-1.79-0.8%$213.75$215.13$211.53695,908
$213.76+5.33+2.6%$209.89$215.55$208.98663,267
$208.43-1.80-0.9%$209.60$210.57$206.71716,947
$210.23-4.19-2.0%$214.25$214.78$208.15636,700
$214.42+4.77+2.3%$212.19$217.57$212.19886,400
$209.65-0.74-0.4%$210.34$215.66$209.36891,300
$210.39-6.36-2.9%$216.86$216.86$209.34812,600
$216.75-1.67-0.8%$218.90$221.99$216.57739,600
$218.42-4.03-1.8%$221.79$227.00$213.201,288,300
$222.45-8.74-3.8%$228.55$229.33$214.681,268,600
$231.19-0.20-0.1%$229.62$235.54$227.00578,900
$231.39-4.65-2.0%$236.40$236.40$228.70862,200
$236.04+0.37+0.2%$235.51$238.87$234.12844,600
$235.67+2.66+1.1%$233.40$237.77$231.70636,600
$233.01+1.49+0.6%$230.33$234.47$229.85740,600
$231.52-0.83-0.4%$231.60$236.00$230.391,001,900
$232.35-5.93-2.5%$236.30$238.00$229.16777,200
$238.28+0.33+0.1%$235.67$238.83$234.63788,300
$237.95+1.67+0.7%$239.12$239.12$235.661,129,600
$236.28+1.40+0.6%$235.82$236.52$232.00551,300
$234.88-5.69-2.4%$239.26$241.33$231.59792,200
$240.57-0.89-0.4%$242.01$243.21$239.78482,000
$241.46+0.72+0.3%$240.87$244.49$238.53499,200
$240.74-3.10-1.3%$244.55$244.55$238.982,214,700
$243.84+0.25+0.1%$246.59$247.31$243.57569,600
$243.59+2.76+1.1%$242.93$244.36$241.76602,200
$240.83-5.04-2.0%$246.81$246.81$239.84702,600
$245.87+0.070.0%$247.68$248.45$244.66465,400
$245.80+5.32+2.2%$244.60$246.73$244.04422,900
$240.48-0.83-0.3%$240.94$244.46$239.291,029,500
$241.31+1.24+0.5%$238.38$241.44$236.00424,500
$240.07-6.74-2.7%$240.00$244.71$239.11467,900
$246.81-0.76-0.3%$246.00$249.00$244.75321,900
$247.57+2.00+0.8%$246.92$248.91$241.87507,600
$245.57+1.86+0.8%$244.00$248.07$241.021,155,900
$243.71-6.97-2.8%$250.13$252.50$243.021,072,800
$250.68+6.14+2.5%$241.39$252.72$241.391,221,000
$244.54-6.56-2.6%$249.48$250.64$244.491,192,900
$251.10+1.81+0.7%$250.00$252.85$246.994,740,300
$249.29-10.94-4.2%$257.40$259.83$248.522,373,000
$260.23+5.76+2.3%$256.36$266.38$254.591,560,100
$254.47+0.19+0.1%$253.66$254.70$250.44419,900
$254.28+5.58+2.2%$248.75$255.85$248.55516,600
$248.70-3.46-1.4%$249.60$254.93$245.76439,900
Ticker
Hamburg:J7Z
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
Hamburg
Currency
EUR

What changed lately

Latest news

All Jazz Pharmaceuticals plc news

Jazz Pharmaceuticals plc on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
36 in the last 12 months · 273 in all · newest Nov 3, 2026 · oldest 2019
Calls
25 calls with a replay · 25 with a transcript · latest Nov 2, 2026
Decks
37 decks · latest September 2026

Where Jazz Pharmaceuticals plc is listed

ListingExchangeCountryCurrency
NASDAQ:JAZZ · Home listingNASDAQUnited StatesUSD
Tradegate:J7ZTradegateGermanyEUR
gettex:J7ZgettexGermanyEUR
LS Exchange:A1JS1KLS ExchangeGermanyEUR
Frankfurt:J7ZFrankfurtGermanyEUR
Lang & Schwarz:A1JS1KLang & SchwarzGermanyEUR
BOATS:JAZZBOATSUnited StatesUSD
Milan:1JAZZMilanItalyEUR
B3:J2AZ34B3BrazilBRL
BMV:JAZZNBMVMexicoMXN
Stuttgart:J7ZStuttgartGermanyEUR
BIVA:JAZZNBIVAMexicoMXN
BX Swiss:J7ZBX SwissSwitzerlandCHF
Dusseldorf:J7ZDusseldorfGermanyEUR
Hamburg:J7Z · This pageHamburgGermanyEUR
Hanover:J7ZHanoverGermanyEUR
Munich:J7ZMunichGermanyEUR
Xetra:J7ZXetraGermanyEUR

Valuation

P/E 72.6× against a median of 41.4×: 8th lowest of 10 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$18.48B USD
P/E
72.6×
EV/sales
3.9×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
3.6×
Gross margin
Not reported
Operating margin
9.0%
Net margin
4.4%
Debt to equity
1.3×
Beta vs S&P 500
0.64

Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Jazz Pharmaceuticals plc · NASDAQ:JAZZUS$14.95BUS$18.48B72.6×3.9×n/a3.6×4.4%1.3×0.64
Innovent Biologics, Inc. · HKEX:1801US$17.82BUS$15.17B146×7.8×75.9×5.7×6.2%0.1×n/a
Yunnan Baiyao Group Co. Ltd. Class A · SZSE:000538US$15.07BUS$13.10B19.4×2.0×n/a2.5×12.2%0.0×n/a
Ipsen SA · EURONEXT:IPNUS$14.62BUS$13.51B30.0×3.4×11.2×2.8×12.1%0.2×n/a
Laurus Labs Ltd. · NSE:LAURUSLABSUS$13.38BUS$13.66B92.5×16.2×53.2×20.5×17.1%0.4×n/a
Zydus Lifesciences Limited · NSE:ZYDUSLIFEUS$12.92BUS$13.86B28.6×4.2×17.9×4.3×13.8%0.5×n/a
Elanco Animal Health Incorporated · NYSE:ELANUS$12.87BUS$15.85Bn/a3.1×13.1×1.9×−2.9%0.5×1.20
Dr. Reddy's Laboratories Ltd. · NSE:DRREDDYUS$12.50BUS$12.45B41.4×3.5×22.6×3.0×8.5%0.2×n/a
Cipla Ltd · NSE:CIPLAUS$12.34BUS$11.26B39.5×3.7×21.6×3.2×10.4%0.0×n/a
Mankind Pharma Ltd. · NSE:MANKINDUS$11.88BUS$12.18B49.1×7.3×27.7×6.3×14.6%0.3×n/a
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. Class A · SSE:600436US$11.62BUS$11.29B58.9×9.5×n/a5.5×16.7%0.0×n/a
Median of the othersUS$12.89BUS$13.31B41.4×4.0×22.1×3.8×12.1%0.2×1.20

Forecasts

13 strong buy · 7 buy · 2 hold · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
297.50 USD · Analysts' mean
EPS, year to Dec 2026
14.90 · 20 analysts
Revenue, year to Dec 2026
4.81B · 21 analysts

Team and board

Officers

OfficerRole
Renee GalaPresident and Chief Executive Officer, Jazz Pharmaceuticals plc
Heather Ann McSharryDirector, International Airlines Group
Laura HamillDirector, BB Biotech, Fate Therapeutics Inc., and Unchained Labs
Patrick G. EnrightManaging Director, Longitude Capital
Patrick KennedyDirector, Jazz Pharmaceuticals plc
Seamus MulliganDirector, Jazz Pharmaceuticals plc
Ted W. LoveDirector, Jazz Pharmaceuticals plc
Thomas RigaChief Business Officer

Board

DirectorRole
Bruce C. CozaddChairperson, Jazz Pharmaceuticals plc
Norbert G. RiedelChairperson, Eton Pharmaceuticals, Inc.
Jennifer E. CookDirector
Mark D. SmithProfessor, University of California, San Francisco and Director, Teladoc Health, Inc. and Phreesia, Inc.
Renee GalaPresident and Chief Executive Officer, Jazz Pharmaceuticals plc
Rick E WinninghamLead Independent Director, Jazz Pharmaceuticals plc

Events

Calls

CallWhenStatus
Jazz Pharmaceuticals (NASDAQ:JAZZ) Q3 2026 Earnings CallMon, Nov 02, 2026 · 4:30 PM ETReplay
Jazz Pharmaceuticals (NASDAQ:JAZZ) Q2 2026 Earnings CallMon, Aug 03, 2026 · 4:30 PM ETReplay
Jazz Pharmaceuticals (NASDAQ:JAZZ) Q1 2026 Earnings CallTue, May 05, 2026 · 4:30 PM ETReplay
Jazz Pharmaceuticals (NASDAQ:JAZZ) Q4 2025 Earnings CallTue, Feb 24, 2026 · 4:30 PM ETReplay
Jazz Pharmaceuticals (NASDAQ:JAZZ) Q3 2025 Earnings CallWed, Nov 05, 2025 · 4:30 PM ETReplay
Jazz Pharmaceuticals (NASDAQ:JAZZ) Q2 2025 Earnings CallTue, Aug 05, 2025 · 4:30 PM ETReplay
Jazz Pharmaceuticals (NASDAQ:JAZZ) Q1 2025 Earnings CallTue, May 06, 2025Replay
Jazz Pharmaceuticals (NASDAQ:JAZZ) Q4 2024 Earnings CallTue, Feb 25, 2025 · 3:30 PM ETReplay
Jazz Pharmaceuticals (NASDAQ:JAZZ) Q3 2024 Earnings CallWed, Nov 06, 2024 · 4:30 PM ETReplay
Jazz Pharmaceuticals (NASDAQ:JAZZ) Q2 2024 Earnings CallWed, Jul 31, 2024 · 4:30 PM ETReplay
All 25 calls
CallWhenStatus
Jazz Pharmaceuticals (NASDAQ:JAZZ) Q1 2024 Earnings CallWed, May 01, 2024 · 4:30 PM ETReplay
Jazz Pharmaceuticals (NASDAQ:JAZZ) Q4 2023 Earnings CallWed, Feb 28, 2024 · 4:30 PM ETReplay
Jazz Pharmaceuticals (NASDAQ:JAZZ) Q3 2023 Earnings CallWed, Nov 08, 2023 · 4:30 PM ETReplay
Jazz Pharmaceuticals (NASDAQ:JAZZ) Q2 2023 Earnings CallWed, Aug 09, 2023 · 4:30 PM ETReplay
Jazz Pharmaceuticals (NASDAQ:JAZZ) Q3 2022 Earnings CallWed, Nov 09, 2022Replay
Jazz Pharmaceuticals (NASDAQ:JAZZ) Q2 2022 Earnings CallWed, Aug 03, 2022 · 9:30 PM ETReplay
Jazz Pharmaceuticals (NASDAQ:JAZZ) Q1 2022 Earnings CallWed, May 04, 2022 · 4:30 PM ETReplay
Jazz Pharmaceuticals (NASDAQ:JAZZ) Q4 2021 Earnings CallTue, Mar 01, 2022 · 4:30 PM ETReplay
Jazz Pharmaceuticals (NASDAQ:JAZZ) Q3 2021 Earnings CallTue, Nov 09, 2021 · 4:30 PM ETReplay
Jazz Pharmaceuticals (NASDAQ:JAZZ) Q2 2021 Earnings CallTue, Aug 03, 2021 · 4:30 PM ETReplay
Jazz Pharmaceuticals (NASDAQ:JAZZ) Q1 2021 Earnings CallTue, May 04, 2021 · 4:30 PM ETReplay
Jazz Pharmaceuticals (NASDAQ:JAZZ) Q4 2020 Earnings CallTue, Feb 23, 2021 · 3:30 PM ETReplay
Jazz Pharmaceuticals (NASDAQ:JAZZ) Q3 2020 Earnings CallMon, Nov 02, 2020 · 3:30 PM ETReplay
Jazz Pharmaceuticals (NASDAQ:JAZZ) Q2 2020 Earnings CallTue, Aug 04, 2020 · 4:30 PM ETReplay
Jazz Pharmaceuticals (NASDAQ:JAZZ) Q1 2020 Earnings CallTue, May 05, 2020 · 4:30 PM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 2, 2026 · After close+7.1%
Q2 2026Aug 3, 2026 · After close+4.0%
Q1 2026May 5, 2026 · After close+7.7%
Q4 2025Feb 25, 2026+8.7%
Q3 2025Nov 5, 2025 · After close−2.3%
Q2 2025Aug 5, 2025 · After close−6.4%
Q1 2025May 6, 2025 · After close−8.8%
Q4 2024Feb 25, 2025 · After close+3.2%
Q3 2024Nov 6, 2024 · After close+6.8%
Q2 2024Jul 31, 2024 · After close+3.8%
All 20 quarters
QuarterResultsShare move
Q1 2024May 1, 2024 · After close−0.9%
Q4 2023Feb 28, 2024 · After close−8.3%
Q3 2023Nov 8, 2023 · After close−9.1%
Q2 2023Aug 9, 2023 · After close+1.6%
Q1 2023May 10, 2023 · After close+0.4%
Q4 2022Mar 1, 2023 · After close+2.7%
Q3 2022Nov 9, 2022 · After close+7.1%
Q2 2022Aug 3, 2022 · After close−0.3%
Q1 2022May 4, 2022 · After close−2.7%
Q4 2021Mar 1, 2022 · After close+12.1%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck27 slidesSeptember 2026
Corporate Update (August 2026)Corporate update23 slidesAug 25, 2026
Q2 2026 Earnings PresentationEarnings25 slidesAug 3, 2026
Q4 2025 Earnings PresentationEarnings29 slidesFeb 24, 2026
Investor Presentation (January 2026)Investor deck39 slidesJan 9, 2026
44th Annual J.P. Morgan Healthcare Conference (January 2026)Conference18 slidesJanuary 2026
Q3 2025 Earnings PresentationEarnings24 slidesNov 5, 2025
Q4 2024 Earnings PresentationEarnings27 slidesFeb 25, 2025
43rd Annual J.P. Morgan Healthcare Conference 2025Conference27 slidesJan 13, 2025
42nd Annual J.P. Morgan Healthcare Conference (January 2024)Conference31 slidesJan 8, 2024
All 37 decks
DeckKindSlidesDate
41st Annual J.P. Morgan Healthcare Conference (January 2023)Conference36 slidesJan 9, 2023
Shareholder Meeting (July 2022)Shareholder meeting11 slidesJul 7, 2022
Shareholder Meeting (July 2021)Shareholder meeting25 slidesJul 14, 2021
Q1 2021 Earnings PresentationEarnings24 slidesMay 4, 2021
Q4 2020 Earnings PresentationEarnings39 slidesFeb 23, 2021
Merger or Acquisition (February 2021)Merger or acquisition21 slidesFeb 4, 2021
39th Annual J.P. Morgan Healthcare Conference (January 2021)Conference11 slidesJan 12, 2021
Q3 2020 Earnings PresentationEarnings33 slidesNov 2, 2020
Q2 2020 Earnings PresentationEarnings38 slidesAug 4, 2020
Q1 2020 Earnings PresentationEarnings26 slidesMay 5, 2020
38th Annual J.P. Morgan Healthcare Conference (January 2020)Conference9 slidesJan 14, 2020
37th Annual J.P. Morgan Healthcare Conference (January 2019)Conference7 slidesJan 8, 2019
36th Annual J.P. Morgan Healthcare Conference 2018Conference8 slidesJan 9, 2018
35th Annual J.P. Morgan Healthcare Conference 2017Conference7 slidesJan 9, 2017
Shareholder Meeting (July 2016)Shareholder meeting34 slidesJul 5, 2016
Merger or Acquisition (May 2016)Merger or acquisition27 slidesMay 31, 2016
34th Annual JP Morgan Healthcare Conference (January 2016)Conference6 slidesJan 12, 2016
33rd Annual J.P. Morgan Healthcare Conference (January 2015)Conference7 slidesJan 13, 2015
Merger or Acquisition (December 2013)Merger or acquisition22 slidesDec 19, 2013
31st Annual J.P. Morgan Healthcare Conference 2013Conference12 slidesJan 11, 2013
Merger or Acquisition (December 2011)Merger or acquisition37 slidesDec 8, 2011
8th Annual Lazard Capital Markets Healthcare Conference (November 2011)Conference40 slidesNov 15, 2011
Merger or Acquisition (October 2011)Merger or acquisition42 slidesOct 19, 2011
UBS Global Life Sciences Conference 2011Conference36 slidesSep 21, 2011
Merger or Acquisition (September 2011)Merger or acquisition27 slidesSep 20, 2011
Investor Presentation (January 2011)Investor deck13 slidesJan 19, 2011
J.P. Morgan Healthcare Conference 2010Conference5 slidesJan 20, 2010

Open Decks

Financings

RaiseDate
1.875% exchangeable senior notes due 2032
Made bigger: US$1.1B
Use of proceeds: General corporate purposes
Aug 27, 2026

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue4.27B4.07B3.83B3.66B3.09B2.36B2.16B1.89B1.62B1.49B
Research and development782.7M884.0M849.7M590.5M505.7M335.4M299.7M226.6M198.4M162.3M
Selling, general and administrative1.81B1.39B1.34B1.42B1.45B854.2M736.9M683.5M544.2M502.9M
Operating income-430.2M716.6M578.6M-65.5M170.3M378.1M532.4M614.8M528.8M591.7M
Depreciation and amortization41.6M32.8M30.4M30.3M26.7M18.7M15.3M15.2M13.1M11.8M
EBITDA-388.6M749.4M609.0M-35.2M197.0M396.8M547.7M630.0M541.9M603.5M
Interest expense32.8M32.8M89.9M87.6M62.5M56.7M37.8M27.5M
Income before tax-627.9M470.4M297.9M-372.8M-112.8M275.1M454.3M529.5M441.1M532.4M
Income tax-272.4M-91.4M-119.9M-158.6M216.1M33.5M-73.2M80.2M-47.7M135.2M
Net income-356.1M560.1M414.8M-224.1M-329.7M238.6M523.4M447.1M487.8M396.8M
Earnings per share, basic-5.849.066.55-3.58-5.524.289.227.458.136.56
Earnings per share, diluted-5.848.656.10-3.58-5.524.229.097.307.966.41

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents1.39B2.41B1.51B881.5M591.4M1.06B637.3M309.6M386.0M366.0M
Receivables830.7M716.8M705.8M651.5M563.4M396.5M356.0M263.8M224.1M234.2M
Inventory417.0M480.4M597.0M714.1M1.07B95.4M78.6M53.0M43.2M34.1M
Current assets4.17B4.63B3.44B2.61B2.61B2.84B1.63B1.23B968.3M748.1M
Property, plant and equipment127.9M131.5M200.4M170.1M107.5M
Goodwill1.83B1.72B1.75B1.69B1.83B958.3M920.0M927.6M947.5M893.8M
Total assets11.7B12.0B11.4B10.8B12.3B6.54B5.54B5.20B5.12B4.80B
Accounts payable122.1M77.9M102.8M90.8M100.3M26.9M45.7M40.6M24.4M22.4M
Current liabilities2.24B1.04B1.54B933.2M809.3M653.7M364.5M345.5M293.9M257.4M
Long-term debt4.33B6.08B5.11B5.69B6.02B1.85B1.57B1.56B1.54B1.99B
Total debt5.36B6.11B5.71B5.72B6.05B2.09B1.61B1.60B1.58B2.03B
Shareholders' equity4.32B4.09B3.74B3.09B3.97B3.66B3.11B2.76B2.71B1.88B
Shares outstanding61.4M60.6M62.3M63.2M61.6M56.2M56.1M57.7M58.9M59.8M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations1.36B1.40B1.09B1.27B778.5M899.6M776.4M798.9M693.1M592.4M
Capital spending-58.8M-38.1M-24.0M-29.0M-27.6M-15.0M-40.1M-20.4M-28.9M-9.69M
Free cash flow1.30B1.36B1.07B1.24B750.9M884.6M736.3M778.5M664.1M582.7M
Cash from investing-1.51B-508.2M-163.1M-446.2M-5.21B-1.01B-155.3M-394.5M-268.9M-1.75B
Cash from financing-873.4M20.5M-305.3M-529.5M3.97B528.1M-293.7M-479.1M-409.1M541.0M
Share buybacks-125.0M-311.4M-269.8M-54.0K0-146.5M-301.4M-523.7M-98.8M-278.3M
Change in cash-1.02B906.6M624.8M290.0M-466.3M420.4M327.7M-76.4M20.1M-622.8M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 10, 2026Insider tradeSEC
4 · Change in ownershipNov 6, 2026Insider tradeSEC
144 · Notice of proposed saleNov 6, 2026Other filingsSEC
4 · Change in ownershipNov 5, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2026Big-stake noticeSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
144 · Notice of proposed saleNov 4, 2026Other filingsSEC
144 · Notice of proposed saleNov 3, 2026Other filingsSEC
144 · Notice of proposed saleNov 2, 2026Other filingsSEC
10-Q · Quarterly reportNov 2, 2026Quarterly reportSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportNov 2, 2026ResultsSEC
8-K · Current reportOct 26, 2026ResultsSEC
8-K · Current reportOct 9, 2026Management or board changeSEC
144 · Notice of proposed saleOct 8, 2026Other filingsSEC
4 · Change in ownershipOct 7, 2026Insider tradeSEC
144 · Notice of proposed saleOct 6, 2026Other filingsSEC
4 · Change in ownershipOct 5, 2026Insider tradeSEC
144 · Notice of proposed saleOct 1, 2026Other filingsSEC
8-K · Current reportSep 23, 2026Material contractSEC
8-K · Current reportSep 15, 2026Current reportSEC
4 · Change in ownershipSep 14, 2026Insider tradeSEC
4 · Change in ownershipSep 10, 2026Insider tradeSEC
4 · Change in ownershipSep 10, 2026Insider tradeSEC
144 · Notice of proposed saleSep 10, 2026Other filingsSEC
144 · Notice of proposed saleSep 8, 2026Other filingsSEC
144 · Notice of proposed saleSep 8, 2026Other filingsSEC
4 · Change in ownershipSep 2, 2026Insider tradeSEC
4 · Change in ownershipSep 2, 2026Insider tradeSEC
4 · Change in ownershipSep 2, 2026Insider tradeSEC
4 · Change in ownershipSep 2, 2026Insider tradeSEC
4 · Change in ownershipSep 2, 2026Insider tradeSEC
4 · Change in ownershipSep 2, 2026Insider tradeSEC
4 · Change in ownershipSep 2, 2026Insider tradeSEC
4 · Change in ownershipSep 2, 2026Insider tradeSEC
4 · Change in ownershipSep 2, 2026Insider tradeSEC
4 · Change in ownershipSep 2, 2026Insider tradeSEC
4 · Change in ownershipSep 2, 2026Insider tradeSEC
144 · Notice of proposed saleSep 1, 2026Other filingsSEC
4 · Change in ownershipAug 31, 2026Insider tradeSEC
8-K · Current reportAug 31, 2026Material contractSEC
144 · Notice of proposed saleAug 31, 2026Other filingsSEC
144 · Notice of proposed saleAug 31, 2026Other filingsSEC
144 · Notice of proposed saleAug 31, 2026Other filingsSEC
144 · Notice of proposed saleAug 31, 2026Other filingsSEC
144 · Notice of proposed saleAug 31, 2026Other filingsSEC
144 · Notice of proposed saleAug 31, 2026Other filingsSEC
144 · Notice of proposed saleAug 31, 2026Other filingsSEC
144 · Notice of proposed saleAug 31, 2026Other filingsSEC
144 · Notice of proposed saleAug 31, 2026Other filingsSEC
144 · Notice of proposed saleAug 31, 2026Other filingsSEC
144 · Notice of proposed saleAug 31, 2026Other filingsSEC
144 · Notice of proposed saleAug 27, 2026Other filingsSEC
8-K · Current reportAug 25, 2026Current reportSEC
8-K · Current reportAug 10, 2026Material contractSEC
8-K · Current reportAug 10, 2026Current reportSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
144 · Notice of proposed saleAug 7, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeAug 6, 2026Big-stake noticeSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
144 · Notice of proposed saleAug 3, 2026Other filingsSEC
10-Q · Quarterly reportAug 3, 2026Quarterly reportSEC
8-K · Current reportAug 3, 2026ResultsSEC
8-K · Current reportJul 24, 2026Meeting outcomeSEC
DEFA14A · Additional proxy materialJul 14, 2026Meeting noticeSEC
4 · Change in ownershipJul 6, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
144 · Notice of proposed saleJul 1, 2026Other filingsSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
144 · Notice of proposed saleJun 15, 2026Other filingsSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
144 · Notice of proposed saleJun 10, 2026Other filingsSEC
ARS · Annual report to shareholdersJun 8, 2026Annual reportSEC
DEFA14A · Additional proxy materialJun 8, 2026Meeting noticeSEC
DEF 14A · Proxy statementJun 8, 2026Meeting noticeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
144 · Notice of proposed saleJun 1, 2026Other filingsSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
PRE 14A · Preliminary proxy statementMay 29, 2026Meeting noticeSEC
8-K · Current reportMay 29, 2026Management or board changeSEC
144 · Notice of proposed saleMay 28, 2026Other filingsSEC
144 · Notice of proposed saleMay 28, 2026Other filingsSEC
4 · Change in ownershipMay 27, 2026Insider tradeSEC
4 · Change in ownershipMay 27, 2026Insider tradeSEC
144 · Notice of proposed saleMay 22, 2026Other filingsSEC
144 · Notice of proposed saleMay 22, 2026Other filingsSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
10-Q · Quarterly reportMay 5, 2026Quarterly reportSEC
8-K · Current reportMay 5, 2026ResultsSEC
144 · Notice of proposed saleMay 1, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeApr 30, 2026Big-stake noticeSEC
10-K/A · Annual report, amendedApr 24, 2026Annual reportSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
144 · Notice of proposed saleApr 1, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 27, 2026Big-stake noticeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
144 · Notice of proposed saleMar 9, 2026Other filingsSEC
144 · Notice of proposed saleMar 5, 2026Other filingsSEC
144 · Notice of proposed saleMar 5, 2026Other filingsSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
144 · Notice of proposed saleMar 3, 2026Other filingsSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 27, 2026Other filingsSEC
144 · Notice of proposed saleFeb 27, 2026Other filingsSEC
144 · Notice of proposed saleFeb 26, 2026Other filingsSEC
144 · Notice of proposed saleFeb 26, 2026Other filingsSEC
144 · Notice of proposed saleFeb 26, 2026Other filingsSEC
10-K · Annual reportFeb 24, 2026Annual reportSEC
8-K · Current reportFeb 24, 2026ResultsSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
8-K · Current reportJan 12, 2026ResultsSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
3 · Initial statement of ownershipDec 10, 2025Insider tradeSEC
144 · Notice of proposed saleDec 9, 2025Other filingsSEC
4 · Change in ownershipDec 9, 2025Insider tradeSEC
4 · Change in ownershipDec 9, 2025Insider tradeSEC
144 · Notice of proposed saleDec 5, 2025Other filingsSEC
4 · Change in ownershipDec 4, 2025Insider tradeSEC
144 · Notice of proposed saleDec 1, 2025Other filingsSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
144 · Notice of proposed saleNov 26, 2025Other filingsSEC
4 · Change in ownershipNov 24, 2025Insider tradeSEC
4 · Change in ownershipNov 21, 2025Insider tradeSEC
4 · Change in ownershipNov 20, 2025Insider tradeSEC
4 · Change in ownershipNov 20, 2025Insider tradeSEC
4 · Change in ownershipNov 20, 2025Insider tradeSEC
144 · Notice of proposed saleNov 20, 2025Other filingsSEC
144 · Notice of proposed saleNov 19, 2025Other filingsSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
144 · Notice of proposed saleNov 18, 2025Other filingsSEC
144 · Notice of proposed saleNov 18, 2025Other filingsSEC
144 · Notice of proposed saleNov 18, 2025Other filingsSEC
144 · Notice of proposed saleNov 17, 2025Other filingsSEC
8-K · Current reportNov 17, 2025Current reportSEC
10-Q · Quarterly reportNov 5, 2025Quarterly reportSEC
8-K · Current reportNov 5, 2025ResultsSEC
8-K · Current reportOct 28, 2025Management or board changeSEC
8-K · Current reportOct 22, 2025Current reportSEC
4 · Change in ownershipOct 3, 2025Insider tradeSEC
144 · Notice of proposed saleOct 3, 2025Other filingsSEC
4 · Change in ownershipSep 17, 2025Insider tradeSEC
4 · Change in ownershipSep 4, 2025Insider tradeSEC
4 · Change in ownershipAug 11, 2025Insider tradeSEC
4 · Change in ownershipAug 11, 2025Insider tradeSEC
4 · Change in ownershipAug 11, 2025Insider tradeSEC
4 · Change in ownershipAug 11, 2025Insider tradeSEC
4 · Change in ownershipAug 11, 2025Insider tradeSEC
4 · Change in ownershipAug 11, 2025Insider tradeSEC
4 · Change in ownershipAug 11, 2025Insider tradeSEC
4 · Change in ownershipAug 11, 2025Insider tradeSEC
4 · Change in ownershipAug 11, 2025Insider tradeSEC
4 · Change in ownershipAug 11, 2025Insider tradeSEC
4 · Change in ownershipAug 11, 2025Insider tradeSEC
4 · Change in ownershipAug 11, 2025Insider tradeSEC
144 · Notice of proposed saleAug 8, 2025Other filingsSEC
144 · Notice of proposed saleAug 8, 2025Other filingsSEC
144 · Notice of proposed saleAug 8, 2025Other filingsSEC
144 · Notice of proposed saleAug 8, 2025Other filingsSEC
UPLOAD · Letter from the SECAug 8, 2025Other filingsSEC
144 · Notice of proposed saleAug 8, 2025Other filingsSEC
144 · Notice of proposed saleAug 8, 2025Other filingsSEC

This page holds 200 of 1,000 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Jazz Pharmaceuticals plc’s releases

Common shares
64,914,577
Fully diluted
64,914,577

Fully diluted

LineShares
Common shares64,914,577

Share count over time

CountShares
Nov 22, 202664,914,577

Open Cap table

Shareholders

Funds

HolderSharesValueAs of
iShares Core S&P Mid-Cap ETF2.15MUS$517MJun 30, 2026
American Funds Fundamental Investors2.1MUS$506MJun 30, 2026
Vanguard Total Stock Market Index Fund1.89MUS$456MJun 30, 2026
Fullerthaler Behavioral Small Cap Equity1.56MUS$376MJun 30, 2026
Vanguard Small-Cap Index Fund1.37MUS$329MJun 30, 2026
Vanguard Small-Cap Value Index Fund866KUS$209MJun 30, 2026
Vanguard Extended Market Index Fund719KUS$173MJun 30, 2026
SMALLCAP World Fund Inc500KUS$120MJun 30, 2026
VictoryShares Free Cash Flow ETF470KUS$113MJun 30, 2026
Franklin Dynatech Fund450KUS$108MJun 30, 2026
Show 50 holders
HolderSharesValueAs of
Select Biotechnology Portfolio410KUS$97.1MMay 31, 2026
JPMorgan Mid Cap Value Fund403KUS$97.2MJun 30, 2026
Fidelity Low-Priced Stock Fund400KUS$101MJul 31, 2026
iShares S&P Mid-Cap 400 Growth ETF375KUS$90.5MJun 30, 2026
Fidelity Balanced Fund367KUS$86.7MMay 31, 2026
PIMCO RAE US Small Fund329KUS$79.2MJun 30, 2026
State Street(R) SPDR(R) Portfolio S&P 400(TM) Mid Cap ETF318KUS$76.5MJun 30, 2026
Fidelity Extended Market Index Fund313KUS$74.1MMay 31, 2026
Strategic Advisers Fidelity U.S. Total Stock Fund313KUS$73.9MMay 31, 2026
BNY Mellon Dynamic Value Fund296KUS$70MMay 31, 2026
Select Pharmaceuticals Portfolio260KUS$61.4MMay 31, 2026
Franklin Biotechnology Discovery Fund258KUS$65.3MJul 31, 2026
iShares Russell Mid-Cap ETF245KUS$59MJun 30, 2026
Select Health Care Portfolio235KUS$55.6MMay 31, 2026
Columbia Overseas Value Fund235KUS$55.5MMay 31, 2026
U.S. Small Cap Portfolio234KUS$59.3MJul 31, 2026
Fidelity Contrafund228KUS$54.9MJun 30, 2026
Fidelity Mid Cap Index Fund226KUS$57.1MJul 31, 2026
Fidelity Value Fund212KUS$53.7MJul 31, 2026
U.S. Targeted Value Portfolio212KUS$53.6MJul 31, 2026
Franklin Growth Opportunities Fund193KUS$48.7MJul 31, 2026
Fidelity SAI Small-Mid Cap Momentum Index Fund186KUS$46.9MJul 31, 2026
Dimensional U.S. Small Cap ETF169KUS$42.6MJul 31, 2026
Strategic Advisers U.S. Total Stock Fund167KUS$39.4MMay 31, 2026
Schwab U.S. Mid-Cap ETF164KUS$38.9MMay 31, 2026
Vanguard Health Care Index Fund164KUS$38.8MMay 31, 2026
iShares U.S. Pharmaceuticals ETF163KUS$39.3MJun 30, 2026
VIP Mid Cap Portfolio161KUS$38.7MJun 30, 2026
AQR Long-Short Equity Fund159KUS$38.4MJun 30, 2026
JPMorgan Mid Cap Equity Fund155KUS$37.4MJun 30, 2026
Avantis U.S. Large Cap Value ETF155KUS$36.6MMay 31, 2026
Dimensional U.S. Core Equity 2 ETF147KUS$37.2MJul 31, 2026
Franklin Small Cap Growth Fund146KUS$36.9MJul 31, 2026
Fidelity Blue Chip Growth Fund138KUS$34.9MJul 31, 2026
Vanguard Strategic Equity Fund134KUS$32.2MJun 30, 2026
iShares Russell 1000 Value ETF133KUS$32.2MJun 30, 2026
Fidelity Advisor Health Care Fund128KUS$32.4MJul 31, 2026
Nuveen Mid Cap Value Fund128KUS$32.3MJul 31, 2026
Pacer US Large Cap Cash Cows Growth Leaders ETF127KUS$32.1MJul 31, 2026
Dimensional U.S. Targeted Value ETF123KUS$31.2MJul 31, 2026

This page holds 50 of 550 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Cozadd Bruce C
Director
Sale27,714USD 234.91US$6.51MNov 6, 2026
Cozadd Bruce C
Director
Sale10,688USD 235.82US$2.52MNov 6, 2026
Cozadd Bruce C
Director
Sale24,483USD 236.84US$5.8MNov 6, 2026
Cozadd Bruce C
Director
Sale5,923USD 237.39US$1.41MNov 6, 2026
Carr Patricia
Officer: SVP, Chief Accounting Officer
Sale1,250USD 231.37US$289KNov 4, 2026
Carr Patricia
Officer: SVP, Chief Accounting Officer
Sale163USD 231.27US$37,697Nov 4, 2026
Gala Renee D
Director, Officer: President & CEO
Sale1,000USD 225.37US$225KNov 3, 2026
Cozadd Bruce C
Director
Sale6,000USD 215.84US$1.3MNov 2, 2026
Gala Renee D
Director, Officer: President & CEO
Sale2,000USD 236.40US$473KOct 6, 2026
Cozadd Bruce C
Director
Sale6,000USD 230.33US$1.38MOct 1, 2026
All 32 trades
TradeTradeSharesPriceValueDate
Patil Neena M
Officer: EVP & Chief Legal Officer
Sale1,200USD 240.94US$289KSep 10, 2026
Gala Renee D
Officer: President & CEO
Sale2,000USD 243.03US$486KSep 8, 2026
Cozadd Bruce C
Director
Sale6,000USD 250.13US$1.5MSep 1, 2026
Iannone Robert
Officer: EVP, Global Head of R&D & CMO
Sale18,187USD 247.86US$4.51MAug 27, 2026
Iannone Robert
Officer: EVP, Global Head of R&D & CMO
Sale11,423USD 248.67US$2.84MAug 27, 2026
Iannone Robert
Officer: EVP, Global Head of R&D & CMO
Sale18,113USD 250.02US$4.53MAug 27, 2026
Iannone Robert
Officer: EVP, Global Head of R&D & CMO
Sale19,639USD 250.60US$4.92MAug 27, 2026
Iannone Robert
Officer: EVP, Global Head of R&D & CMO
Sale9,259USD 251.95US$2.33MAug 27, 2026
Iannone Robert
Officer: EVP, Global Head of R&D & CMO
Sale300USD 252.76US$75,828Aug 27, 2026
Cozadd Bruce C
Director
Sale6,000USD 252.98US$1.52MAug 3, 2026
Cozadd Bruce C
Director
Sale6,000USD 240.47US$1.44MJul 1, 2026
Smith Mark Douglas
Director
Sale1,157USD 230.55US$267KJun 15, 2026
Patil Neena M
Officer: EVP & Chief Legal Officer
Sale1,200USD 231.83US$278KJun 10, 2026
Cozadd Bruce C
Director
Sale6,000USD 235.12US$1.41MJun 1, 2026
Patil Neena M
Officer: EVP & Chief Legal Officer
Sale1,192USD 236.97US$282KMay 28, 2026
Pearce Samantha
Officer: EVP, Chief Commercial Officer
Sale6,907USD 235.41US$1.63MMay 28, 2026
Winningham Rick E
Director
Sale2,741USD 241.57US$662KMay 22, 2026
McSharry Heather Ann
Director
Sale2,000USD 241.00US$482KMay 22, 2026
Cozadd Bruce C
Director
Sale6,000USD 203.33US$1.22MMay 1, 2026
Cozadd Bruce C
Director
Sale3,684USD 190.22US$701KApr 1, 2026
Cozadd Bruce C
Director
Sale2,292USD 190.94US$438KApr 1, 2026
Cozadd Bruce C
Director
Sale24USD 191.74US$4,602Apr 1, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Ted W Love
Other companies: Lisata Therapeutics, Inc. (Director · Since at least Sep 17, 2026); Gilead Sciences, Inc. (Director · Since at least Feb 1, 2024); Structure Therapeutics, Inc. (Director · Since at least Aug 3, 2023); Royalty Pharma plc (Director · Since at least Jul 30, 2020); Seagen Inc (Director · Aug 16, 2020 – Dec 14, 2023 · Past); Portola Pharmaceuticals Inc (Director · Sep 18, 2019 – Jul 2, 2020 · Past); Global Blood Therapeutics Inc (President and CEO, Director · Aug 11, 2015 – Oct 5, 2022 · Past); Cascadian Therapeutics Inc (Director · Sep 5, 2013 – Mar 9, 2018 · Past); Savara, Inc. (Director · Sep 5, 2012 – Jun 19, 2013 · Past); Humanigen Inc (Director · Aug 10, 2012 – Jul 10, 2015 · Past); Amicus Therapeutics Inc (Director · Jun 13, 2012 – Jun 4, 2020 · Past); Bio-Rad Laboratories, Inc. (Director · Mar 24, 2010 – Mar 24, 2010 · Past); Onyx Pharmaceuticals Inc (EVP, R&D and Tech. Operations · Feb 1, 2010 – Jul 25, 2012 · Past); Affymax Inc (Director · Dec 14, 2006 – Jun 13, 2012 · Past); Santarus Inc (Director · Jun 7, 2006 – Jan 2, 2014 · Past); Oruka Therapeutics, Inc. (Director · Mar 7, 2006 – Feb 5, 2010 · Past)
Director · Since at least Dec 1, 2025
Kathryn Falberg
Other companies: Nuvation Bio Inc. (Board of Directors · Since at least Feb 10, 2021); Arcus Biosciences, Inc. (Board Member · Since at least Mar 14, 2018); The Trade Desk, Inc. (Director · Since at least Sep 20, 2016); UroGen Pharma Ltd. (Director · Jan 1, 2019 – Jun 7, 2021 · Past); Tricida Inc (Director · Jun 27, 2018 – Jun 15, 2022 · Past); Sio Gene Therapies Inc (Director · Apr 7, 2017 – May 15, 2017 · Past); BioMarin Pharmaceutical Inc. (Director · Jul 15, 2016 – Jul 15, 2016 · Past); Aimmune Therapeutics Inc (Director · Aug 5, 2015 – Oct 10, 2020 · Past); aTyr Pharma, Inc. (Director · May 6, 2015 – May 24, 2016 · Past); Medivation Inc (Director · Jan 31, 2013 – Sep 28, 2016 · Past); Novelion Therapeutics Inc (Director · Mar 25, 2009 – May 26, 2011 · Past); Oruka Therapeutics, Inc. (CFO and COO · Feb 23, 2009 – Jun 25, 2009 · Past); Halozyme Therapeutics, Inc. (Director · May 15, 2007 – May 4, 2016 · Past)
EVP and CFO · Dec 1, 2009 – Mar 5, 2014 · Past
Karen Smith
Other companies: Context Therapeutics Inc. (Independent Director · Since at least Sep 4, 2024); Skye Bioscience, Inc. (Director · Since at least Jul 2, 2024); Sangamo Therapeutics, Inc. (Director · Since at least Jun 26, 2018); Aurinia Pharmaceuticals Inc (Director · Aug 18, 2023 – Nov 21, 2024 · Past); Quince Therapeutics, Inc. (Chief Medical Officer · May 19, 2022 – Feb 1, 2023 · Past); Tourmaline Bio Inc. (Director · May 16, 2022 – Jun 13, 2023 · Past); Emergent BioSolutions Inc. (EVP, Chief Medical Officer · May 21, 2020 – May 7, 2021 · Past); Antares Pharma Inc (Director · Mar 1, 2019 – May 24, 2022 · Past); Acceleron Pharma Inc (Director · Nov 15, 2017 – Nov 19, 2021 · Past); Sucampo Pharmaceuticals Inc (Director · Jul 15, 2017 – Feb 13, 2018 · Past)
EVP, R&D and CMO · Apr 13, 2015 – Mar 5, 2018 · Past
Catherine Angell Sohn
Other companies: Maze Therapeutics, Inc. (Director · Since at least Jan 30, 2025); Altimmune, Inc. (Director · Since at least Mar 23, 2023); Axcella Health Inc (Director · Aug 21, 2019 – May 19, 2022 · Past); Rubius Therapeutics Inc (Director · Jul 17, 2018 – May 12, 2022 · Past); Palisade Bio, Inc. (Director · Jan 13, 2014 – Jul 1, 2015 · Past); Lifecore Biomedical, Inc. (Director · Nov 13, 2012 – Jun 4, 2022 · Past)
Director · Jul 27, 2012 – Aug 11, 2023 · Past
Karen J. Wilson
Other companies: Connect Biopharma Holdings Limited (Board Director · Since at least Mar 16, 2026); Serina Therapeutics, Inc. (Director · Since at least Jan 14, 2025); LAVA Therapeutics NV (Director · Since at least Jan 1, 2025); Elicio Therapeutics, Inc. (Director · Since at least Feb 4, 2021); Vaxart, Inc. (Director · Aug 25, 2020 – Jun 16, 2021 · Past)
SVP, Finance & PAO · Mar 9, 2011 – Mar 5, 2019 · Past
Norbert Riedel
Other companies: Eton Pharmaceuticals, Inc. (Chairman · Since at least Nov 9, 2018); Cerevel Therapeutics Holdings Inc (Director · Oct 27, 2020 – Aug 1, 2024 · Past); Aptinyx Inc (EXECUTIVE CHAIRMAN OF THE BOD, Director · Jun 20, 2018 – Jan 3, 2023 · Past); Ariad Pharmaceuticals Inc (Director · Apr 28, 2011 – Feb 16, 2017 · Past); Baxter International Inc. (Corporate Vice President · Mar 14, 2006 – Jan 16, 2013 · Past)
Chairperson, Eton Pharmaceuticals, Inc. · Since at least May 2, 2013
Paul L. Berns
Other companies: Kardigan, Inc. (Director · Since at least Jun 17, 2026); Metsera, Inc. (Director · Since at least Jan 30, 2025); Neumora Therapeutics, Inc. (See Remarks, Director · Since at least Sep 14, 2023); EQRx Inc (Director · Dec 17, 2021 – Nov 9, 2023 · Past); Unity Biotechnology Inc (Director · Jun 24, 2021 – Jun 21, 2024 · Past)
Director · Nov 2, 2020 – Aug 5, 2021 · Past
Robert Iannone
Other companies: Pliant Therapeutics, Inc. (Director · Since at least Jul 9, 2026); Autolus Therapeutics plc (Chair of the Research & Development Committee · Since at least Mar 18, 2026); Iteos Therapeutics Inc (Director · Apr 29, 2021 – Jun 11, 2024 · Past); Jounce Therapeutics Inc (Director · Jan 21, 2020 – May 3, 2023 · Past); Immunomedics Inc (CHIEF MEDICAL OFFICER · Apr 12, 2018 – Mar 14, 2019 · Past)
EVP, Global Head of R&D & CMO · Since at least May 29, 2019
Michael P. Miller
Other companies: Rigel Pharmaceuticals, Inc. (Director · Since at least Feb 1, 2026); BioXcel Therapeutics, Inc. (Director · Since at least Jul 1, 2022); Puma Biotechnology Inc (Director · Since at least Feb 23, 2018); VIVUS Inc (Chief Commercial Officer · Apr 26, 2010 – Jan 25, 2013 · Past)
EVP, US Commercial · Jul 31, 2014 – Mar 12, 2020 · Past
Renée Galá
Other companies: DexCom, Inc. (Director · Since at least Mar 6, 2025); Gossamer Bio, Inc. (Director · Feb 7, 2019 – Jun 8, 2023 · Past); Corcept Therapeutics Incorporated (Director · Mar 6, 2018 – Aug 20, 2018 · Past); Theravance Biopharma, Inc. (SVP, Chief Financial Officer · Nov 20, 2017 – Nov 20, 2018 · Past)
President & CEO, Director · Since at least Mar 16, 2020
All 40 people
PersonSeat
Russell J. Cox
Other companies: Gossamer Bio, Inc. (Director · Since at least Feb 7, 2019); Immunic, Inc. (Chief Executive Officer, Director · Jan 3, 2018 – Jan 11, 2019 · Past); Spyre Therapeutics, Inc. (Director · Apr 6, 2016 – Jun 22, 2023 · Past)
EVP & COO · Feb 8, 2011 – Dec 11, 2017 · Past
Jennifer E. Cook
Other companies: BridgeBio Pharma, Inc. (Director · Since at least Jun 21, 2024); Denali Therapeutics Inc. (Director · Since at least May 31, 2024)
Director · Since at least Dec 4, 2023
Kim Sablich
Other companies: Eiger Biopharmaceuticals Inc (Director · Apr 23, 2021 – Mar 1, 2023 · Past); Myovant Sciences Ltd (Chief Commercial Officer · Dec 1, 2018 – Apr 3, 2020 · Past)
EVP, GM of U.S. · Jun 1, 2020 – Jun 5, 2023 · Past
Mark D. Smith
Other companies: Phreesia, Inc. (Board Member · Since at least Jul 17, 2019); Teladoc Health, Inc. (Director · Since at least Oct 22, 2018)
Professor, University of California, San Francisco and Director, Teladoc Health, Inc. and Phreesia, Inc. · Since at least Dec 1, 2020
Matthew Young
Other companies: CytomX Therapeutics, Inc. (Director · Since at least Oct 7, 2015); PRA Health Sciences Inc (Director · Feb 9, 2015 – Jul 1, 2021 · Past)
EVP & CFO · Mar 9, 2014 – Mar 5, 2019 · Past
Suzanne Sawochka Hooper
Other companies: Eidos Therapeutics Inc (Director · Aug 6, 2020 – Jan 26, 2021 · Past); NGM Biopharmaceuticals Inc (Director · Apr 3, 2019 – Apr 5, 2024 · Past)
EVP & General Counsel · Mar 12, 2012 – Feb 25, 2019 · Past
Ted W. Love
Other companies: Gilead Sciences, Inc. (Director · Since at least May 4, 2026); Royalty Pharma plc (Board Member · Since at least Sep 29, 2025)
Director, Jazz Pharmaceuticals plc · Since at least Nov 5, 2025
Bruce C. Cozadd
Other companies: Acelyrin, Inc. (Director · May 4, 2023 – May 21, 2025 · Past)
Director · Since at least Oct 1, 2020
Michael A DesJardin
Other companies: Horizon Pharma PLC (EVP, Technical Operations · Feb 22, 2017 – Feb 20, 2019 · Past)
SVP, Product Development · Feb 8, 2011 – Aug 13, 2011 · Past
Neena M Patil
Other companies: Teleflex Incorporated (Director · Since at least Apr 29, 2022)
EVP & Chief Legal Officer · Since at least Jul 29, 2019
Patrick G. Enright
Other companies: Veradermics, Incorporated (Board Member · Since at least Nov 5, 2026)
Managing Director, Longitude Capital · Since at least Aug 5, 2026
Rick E Winningham
Other companies: Theravance Biopharma, Inc. (CHIEF EXECUTIVE OFFICER, Director · Since at least May 20, 2025)
Director · Since at least Aug 7, 2025
Anne ORiordanDirector · Since at least Feb 14, 2019
Carol A GambleSVP and General Counsel · Nov 30, 2011 – Mar 9, 2012 · Past
Christopher J ToveyEVP, COO & Managing Director E · May 5, 2022 – Jul 5, 2022 · Past
E Alexander AlbertDirector · Jul 16, 2008 – Aug 15, 2008 · Past
Elmar SchneeDirector · Aug 1, 2014 – Aug 5, 2021 · Past
Finbar LarkinSVP, Technical Operations · Oct 31, 2019 – Mar 3, 2023 · Past
Heather Ann McSharryDirector, International Airlines Group · Since at least Aug 7, 2025
Janne LT WisselSVP, Chief Regulatory Officer · May 31, 2007 – May 31, 2011 · Past
Laura HamillDirector · Since at least Aug 5, 2026
Mary Elizabeth HendersonSVP, Technical Operations · Since at least Aug 3, 2023
Patricia CarrSVP, Chief Accounting Officer · Since at least Aug 7, 2019
Patrick KennedyDirector, Jazz Pharmaceuticals plc · Since at least Mar 1, 2024
Paul TreacySVP, Technical Operations · Jul 31, 2014 – Aug 12, 2019 · Past
Rick E WinninghamLead Independent Director, Jazz Pharmaceuticals plc · Since at least Jul 10, 2025
Robert M MyersPresident, Director · May 28, 2010 – Nov 30, 2010 · Past
Samantha PearceEVP, Chief Commercial Officer · Since at least Jan 17, 2024
Seamus MulliganDirector, Jazz Pharmaceuticals plc · Since at least Aug 5, 2022
Thomas RigaChief Business Officer · Since at least Jan 8, 2026

Open People

Log in to ask 6ix AI your own questions about Jazz Pharmaceuticals plc.